Healthcare >> CEO Interviews >> October 5, 2000

H. Joseph Reiser – Cytogen Corporation (cyto)

DR. H. JOSEPH REISER, President and Chief Executive Officer of CYTOGEN Corporation, gained most of his pharmaceutical experience at Berlex Laboratories, the US subsidiary of Schering AG, where he held positions of increasing responsibility since 1981, culminating in his appointment to Corporate Vice President and General Manager, Pharmaceuticals. In 1993 Berlex selected Dr. Reiser as its first Vice President of Technology and Industry Relations. Prior to that time he was Vice President of R&D responsible for preclinical research and development activities. His initial assignment at Berlex was to build a drug discovery effort via his appointment as Director of Pharmacology in 1981. Also during his tenure at Berlex, Dr. Reiser served as the first President of Schering Berlin's Venture Corporation from 1993 to 1994, where he secured funding participation in diverse areas of pharmaceutical R&D and joint ventures. In addition, Dr. Reiser was active in US-based and international licensing activities. Dr. Reiser joined Cytogen in August 1998 and has since that time lead the strategic repositioning of Cytogen in the area of oncology and proteomics. Dr. Reiser received his PhD in Physiology from Indiana University School of Medicine, where he also earned his Master's and Bachelor's of Science degrees. He has held various teaching positions and has been awarded fellowships at the Likoff Cardiovascular Institute, the American Heart Association (AHA) and the National Institutes of Health. He also has served on Editorial Boards, on the Steering Committee of the Pharmaceutical Manufacturers Association and the Boards of several companies, including Berlex. He has authored more than 70 publications and presentations. Profile
TWST: Could we begin with an overview of CYTOGEN Corporation?

Dr. Reiser: CYTOGEN is a well-established biopharmaceutical company

which recently celebrated 20 years of existence. Historically,